Glionova Therapeutics Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 2
Employees
  • Latest Deal Type
  • Out of Business

Glionova Therapeutics General Information

Description

Developer of therapies created to treat cancer. The company's candidate, GLN-1001, is a orally available oncolytic small molecule, currently being developed as a potentially disease modifying therapy for glioblastoma by targeting specific vulnerabilities in tumor cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Primary Office
  • Västra trädgårdsgatan 15
  • 111 53 Stockholm
  • Sweden
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Glionova Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 00.000 Completed Out of Business
2. Grant 20-Nov-2014 00000 00.000 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 12-Nov-2014 $5.75M $5.75M Completed Pre-Clinical Trials
To view Glionova Therapeutics’s complete valuation and funding history, request access »

Glionova Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial